Antipsychotics · Haldol
Haloperidol (Haldol) Side Effects: When CYP2D6 Genetics Are Behind Them
Haloperidol's side-effect profile varies widely between patients on the same dose. CYP2D6 phenotype explains a meaningful portion of that variation, and the Dutch Pharmacogenetics Working Group provides specific dose recommendations based on it.
Haloperidol works, but it is one of the more side-effect-heavy antipsychotics. Extrapyramidal symptoms (EPS), sedation, and dose-related cardiac effects vary widely between patients on the same dose. CYP2D6 phenotype explains a meaningful chunk of that variation: poor metabolizers reach much higher plasma concentrations on standard doses and carry higher EPS risk.
Common reasons this happens
EPS is dose-related
Akathisia (restlessness), Parkinsonism (stiffness, tremor, slowed movement), and dystonia (involuntary muscle contractions) all track with dose. The higher the haloperidol concentration, the more dopamine receptors are blocked, and the more likely EPS is to show up.
Concurrent medications
CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) reduce haloperidol clearance and can turn a normal metabolizer into a phenocopy of a poor metabolizer. EPS that shows up after starting a new medication is often a CYP2D6 interaction.
Long-term effects
Tardive dyskinesia (TD) is a less reversible movement disorder that can develop after months or years of antipsychotic exposure. Higher cumulative drug exposure raises the risk, which is part of why CYP2D6 status matters even before any acute side effect appears.
Poor metabolizers reach much higher haloperidol concentrations and have higher rates of EPS. DPWG recommends roughly 50 percent dose reduction for poor metabolizers, or a switch to a drug that does not lean on CYP2D6.
How your genetics can play a role
CYP2D6 is the main pharmacogenetic factor for haloperidol.[1] Other enzymes (CYP3A4, glucuronidation) play a smaller role.
| Gene | What it affects |
|---|---|
| CYP2D6 | CYP2D6 is one of the main enzymes that clear haloperidol.[1] Reduced enzyme activity slows clearance and raises plasma concentrations at any given dose. Higher concentrations mean higher D2 receptor occupancy and higher EPS risk. |
Poor metabolizers reach much higher haloperidol concentrations and have higher rates of EPS. Intermediate metabolizers fall in between. DPWG recommends a 30 to 50 percent dose reduction for intermediate metabolizers and roughly 50 percent for poor metabolizers, or a switch to an antipsychotic that does not lean on CYP2D6.[2] Ultrarapid metabolizers may get an inadequate response at standard doses.[3]
Want to know what your genetics say about how you'll respond to Haloperidol?
A Gene2Rx report reads your own DNA to show how it may affect your response to Haloperidol and your other medications.
Find out todayWhen to consider pharmacogenetic testing
Most useful before starting haloperidol, or after early EPS or sedation that the dose alone does not explain. CYP2D6 testing is also worth considering if you have had EPS on multiple CYP2D6-metabolized antipsychotics (haloperidol, aripiprazole, brexpiprazole). That pattern suggests reduced CYP2D6 activity.
What you can do next
- If EPS is mild and recent, your prescriber may try a dose reduction or add a short course of benztropine or diphenhydramine while reassessing.
- If EPS is severe or persistent, an antipsychotic switch is usually a better answer than dose adjustments alone. Quetiapine, olanzapine, and clozapine carry lower EPS risk.
- Review all concurrent medications for CYP2D6 inhibitors. Removing or substituting an inhibitor can resolve dose-related side effects without changing the antipsychotic.
- Get CYP2D6 testing if you have had recurrent EPS on multiple antipsychotics. The result will inform your medication choices for years.
Related medications
Related guides
- Zuclopenthixol (Clopixol) Side Effects: CYP2D6 Genetics Explained
- Quetiapine (Seroquel) Side Effects: When CYP3A4 Genetics Make It Harder
- Metoprolol Side Effects: Why This Beta-Blocker Hits Some People Harder
- Paroxetine Side Effects: Why Paxil Hits Some People Harder
- Venlafaxine Side Effects: When Effexor's Side Effects Are Too Much
- 23andMe Drug Response: What You'll Actually See in a Report From Your Data
Frequently asked questions
What's the difference between EPS and tardive dyskinesia?
EPS is the broad term for movement-related side effects that show up during antipsychotic therapy: Parkinsonism, akathisia, dystonia. Most EPS reverses when the drug is reduced or stopped. Tardive dyskinesia is a specific form of involuntary movement disorder (typically of the face and tongue) that develops after long-term antipsychotic exposure and can persist after the drug is stopped.
If I had EPS on haloperidol, will I have it on quetiapine too?
Usually not. Quetiapine carries lower EPS risk than haloperidol because of its different receptor binding profile and shorter D2 occupancy. Quetiapine is metabolized by CYP3A4 rather than CYP2D6, so the CYP2D6 issue does not carry over either.
Is haloperidol still used given the side effects?
Yes, especially for acute psychotic episodes, severe agitation, and emergency psychiatric care. The rapid onset and reliable D2 blockade matter in those settings. For chronic outpatient management, second-generation antipsychotics with lower EPS risk are usually preferred.
References
- U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling (2024). fda.gov
- DPWG / KNMP, via PharmGKB. Dutch Pharmacogenetics Working Group (DPWG) Guidelines. pharmgkb.org
- Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC Guidelines. cpicpgx.org
Disclaimer: This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making changes to your medication. Never stop or change a medication without medical supervision.